FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Next >>
 
TXT Califf Sees Misinformation as Cause of Preventable Deaths
02/17/2023
 
 
TXT GE Recalls ‘Unstable’ Nuclear Medicine Devices
02/16/2023
 
 
TXT Drug R&D Can’t Justify High Prices: Study
02/16/2023
 
 
TXT Further FDA Opioid Crisis Strategies: Califf
02/16/2023
 
 
TXT 30 New Product-Specific Guidances Out
02/16/2023
 
 
TXT Pfizer Says Talzenna Prostate Cancer Study ‘Positive’
02/16/2023
 
 
TXT FDA Approves BioVex BLA Supplement
02/16/2023
 
 
TXT GAO Identifies FDA Gaps in IRB Oversight
02/16/2023
 
 
TXT FDA Pushed Into Accelerated Approval Pricing Model
02/15/2023
 
 
TXT MCM Annual Report Achievements
02/15/2023
 
 
TXT FDA Keeps Concert Drug’s Breakthrough Status
02/15/2023
 
 
TXT Court Action on 3 Claims Explained
02/15/2023
 
 
TXT Pediatric Drug Extrapolation in U.S. Analyzed
02/15/2023
 
 
TXT Bryan Concerns About Gene Therapy Accelerated OKs
02/15/2023
 
 
TXT FDA Facing Backlog of ODE Determinations: Attorneys
02/15/2023
 
 
TXT AdvaMed Comments on Inspection Delay Guidance
02/15/2023
 
 
TXT Panel Unanimously Backs Non-Rx Narcan
02/15/2023
 
 
TXT CGMP Violations in Delta Kozmetik Sanayi Inspection
02/14/2023
 
 
TXT Multiple Violations in Unapproved Wintech Medipro Masks
02/14/2023
 
 
TXT 11 Republicans See FDA/Industry ‘Revolving Door’
02/14/2023
 
 
TXT FDA Alternative Review Tools ‘Critical’ in Decisions: Study
02/14/2023
 
 
TXT Marks Wants ‘Project Orbis’ for Cell/Gene Therapies
02/14/2023
 
 
TXT FDA Learning to Combat Social Media Disinformation
02/14/2023
 
 
TXT Benefit-Risk is Top CBER Panel Issue: FDA
02/13/2023
 
 
TXT Ocuphire Pharma NDA for Eye Dilation Reversal
02/13/2023
 
 
TXT Repackaging Propofol During Covid Guide Withdrawn
02/13/2023
 
 
TXT 10% of FDA-approved Drugs Had Null Findings: JAMA
02/13/2023
 
 
TXT Inspection Troubles Hit Biocon’s Avastin Biosimilar
02/13/2023
 
 
TXT Ethicon $10 Million Settlement Over Surgical Mesh
02/13/2023
 
 
TXT Neonatal Neurodevelopmental Safety Study Guide
02/10/2023
 
 
TXT ODAC Panel Backs Proposed Jemperli Studies
02/10/2023
 
 
TXT New AI Tools Will Require FDA Flexibility: Califf
02/10/2023
 
 
TXT HHS Roadmap Outlines FDA Flexibilities Post-Covid
02/10/2023
 
 
TXT Phathom Gets 2 Complete Response Letters Over Impurity
02/10/2023
 
 
TXT FDA to Explain Post-Health Emergency Effects
02/09/2023
 
 
TXT Eiger Won’t Seek EUA for Interferon Covid Treatment: Bloomberg
02/09/2023
 
 
TXT FDA Updates Philips MDRs; 82 Deaths in 2 Months
02/09/2023
 
 
TXT FDA Denies DuraSeal Spinal Sealant Petition
02/09/2023
 
 
TXT DoJ Wants Conspiracy Charge Against KVK-Tech
02/09/2023
 
 
TXT Senate Judiciary Committee Clears 5 Drug Bills
02/09/2023
 
 
TXT CBER in a ‘Transition Year’: Marks
02/08/2023
 
 
TXT EUA for BD Combination Covid-Flu-RSV Test
02/08/2023
 
 
TXT FDA Unsure of ‘Unprecedented’ Jemperli Trial Plans
02/08/2023
 
 
TXT Industry VMSR Improvement Suggestions
02/08/2023
 
 
TXT CDER Researches Convolutional Neural Networks
02/08/2023
 
 
TXT Califf Sails Through 1st Covid Oversight Hearing
02/08/2023
 
 
TXT QS, Other Violations at Getsch+Hiller Medizintechnik
02/07/2023
 
 
TXT FDA Criminal Probe Nets Device Maker Indictment
02/07/2023
 
 
TXT 8 Inspection Takeaways from New FDA Law
02/07/2023
 
 
TXT OCE Slowed New Projects in 2022
02/07/2023
 
 
TXT Comments on FDA/Patent Office Collaboration
02/07/2023
 
 
TXT Kessler Praises Marks on Covid Response Leadership
02/07/2023
 
 
TXT Lower Added Benefit Associated with Higher DTC Spend
02/07/2023
 
 
TXT Court Throws Out PhRMA Lawsuit on Drug Importation
02/07/2023
 
 
TXT FDA Offers Advisory Committee Hearing on Intarcia Dispute
02/07/2023
 
 
TXT FDA Urges Reporting of Home Covid Test Results
02/06/2023
 
 
TXT Rapid-Acting Depression Drug Gets Priority Review
02/06/2023
 
 
TXT MD Sentenced in Avanir Kickbacks
02/06/2023
 
 
TXT Abbott Expanded Indication for Ablation Catheter
02/06/2023
 
 
TXT Tezspire Approved as Pre-filled Pen for Asthma
02/06/2023
 
 
TXT Sandoz Prolia/Xgeva Biosimilar BLA Submitted
02/06/2023
 
 
TXT Man Fakes Cancer to Skip FDA Misbranding Trial
02/03/2023
 
 
TXT Device Co. Pays $500K over False Claims: DoJ
02/03/2023
 
 
TXT Trodelvy OK’d for Pre-treated Metastatic Breast Cancer
02/03/2023
 
 
TXT Senators Urge Danco Labs to Expand Mifepristone’s Use
02/03/2023
 
 
TXT Attorneys Dismiss ‘Hype’ on FDORA Animal Testing Provision
02/03/2023
 
 
TXT FDA Clinical Hold on 4D Molecular Fabry Drug
02/03/2023
 
 
TXT Device Conformity Assessment Pilot Becoming Permanent
02/03/2023
 
 
TXT GSK’s Oral Anemia Drug Approved for Dialysis
02/02/2023
 
 
TXT Greenleaf Health Hires 2 Former FDA Officials
02/02/2023
 
 
TXT FDA Warning, Import Alert on Contaminated Eyedrops
02/02/2023
 
 
TXT Philips BiPAP, CPAP Mask Recall is Class 1: FDA
02/02/2023
 
 
TXT FDA Strategy on Opioid Reversal Products Nears Fruition
02/02/2023
 
 
TXT PMR/PMC Annual Statistical Report
02/02/2023
 
 
TXT Consider Mfg. Issues in Preparedness Planning: GAO
02/02/2023
 
 
TXT GoodRx Paying $1.5 Million for Consumer Data Breach
02/02/2023
 
 
TXT Ways to Mitigate Park Doctrine Risks: Attorney
02/02/2023
 
 
TXT Expanded Indication for Abbott Heart Catheter
02/02/2023
 
 
TXT Fraudulent Contract Research Org. Leads to Debarment
02/02/2023
 
 
TXT Glucosamine Case Can Inform Drug, Device Cases: Attorney
02/02/2023
 
 
TXT M13A Bioequivalence Consensus Guideline
02/01/2023
 
 
TXT Positive Covid Test Requirement Lifted on 2 Therapeutics
02/01/2023
 
 
TXT No Justification for Lexicon Hearing: CDER
02/01/2023
 
 
TXT CDER Planning 98 New, Revised Guidances for 2023
02/01/2023
 
 
TXT Lyme Disease Drug Development Guidance
02/01/2023
 
 
TXT IBSA Recalls Some Tirosint-Sol Lots
02/01/2023
 
 
TXT Clarius Mobile’s Musculoskeletal AI Measurer
02/01/2023
 
 
TXT Xenex Files De Novo for Disinfection Device
02/01/2023
 
 
TXT RightEye Promoting Off-Label Use: FDA
01/31/2023
 
 
TXT Multiple Violations at Adept Life Science
01/31/2023
 
 
TXT GDUFA 2022 Science and Research Report
01/31/2023
 
 
TXT Improve Biosimilar Development and Approval Efficiency
01/31/2023
 
 
TXT Externally Controlled Trial Guidance
01/31/2023
 
 
TXT FDA 'Defying' Appeals Court is Troubling: Attorneys
01/31/2023
 
 
TXT CBER 2023 Guidance Agenda
01/31/2023
 
 
TXT Biden Administration Ending Public Health Emergency 5/11
01/31/2023
 
 
TXT CBER Tissues/Advanced Therapies Director Bryan Retiring
01/31/2023
 
 
TXT Califf Proposes ‘Transformation’ of Foods Program, ORA
01/31/2023
 
 
TXT Class 1 Recall of Smiths CADD Infusion Sets
01/31/2023
 
 
TXT Guide on Lasers for Surveying, Leveling and Aligning
01/30/2023
 
 
<< Prev  13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving